Vyvanse (lisdexamfetamine dimesylate) was approved by the U.S. Food and Drug Administration (FDA) on Friday as the first medication permitted to treat binge-eating disorder in adults. Read More »

Amgen’s Phase 3 study assessing the safety and effectiveness of biosimilar candidate ABP 501 versus Humira in patients with moderate to sever rheumatoid arthritis revealed positive results. Read More »

Under a final agreement between AstraZeneca and Actavis, AstraZeneca will procure the rights to Actavis’ proprietary respiratory business in the United States and Canada, the two companies announced on Feb. 5. Read More »

TissuGlu, the first tissue adhesive permitted for internal use, was approved Wednesday by the U.S. Read More »

Pfizer said on Wednesday that the U.S. Food and Drug Administration has accepted for review the supplemental New Drug Application (sNDA) for XELJANZ, a medication for treating moderate to severe chronic plaque psoriasis. Read More »

Daiichi Sankyo Co., Ltd., said Wednesday that it has enrolled the first patients in its initial large-scale and multinational clinical studies program to assess the efficiency and safety of mirogabalin, an investigational treatment for diabetic peripheral neuropathic (DPNP) and postherpetic neuralgia (PHN). Read More »

TeaserConcert Pharmaceuticals announced Wednesday that James V. Read More »

TeaserAlbireo announced Thursday that it is beginning a phase II trial with the company’s lead compound for cholestatic liver disease and NASH, A4250. Read More »

TeaserHelsinn Healthcare S.A. Read More »

An American Pharmacists Association (APhA) official released a statement on Thursday, stressing the important role of childhood and booster vaccinations in the protection of individual lives and overall public health. Read More »

Pharmacy Today released the findings of its annual survey on over-the-counter (OTC) products on Thursday, conducted by the American Pharmacists Association, revealing which OTC products were recommended most frequently by U.S. pharmacists during July 2014. Read More »

Acura Pharmaceuticals said on Thursday that it has launched NEXAFEDÂ Sinus Pressure + Pain, a pseudoephedrine, methamphetamine-resistant, immediate-release tablet that relieves congestion, pain and fever from colds and allergies. Read More »

The U.S. Food and Drug Administration said on Tuesday that is has approved the use of Pfizer's palbociclib oral capsules, in combination with letrozole, to treat advanced breast cancer. Read More »

TeaserUpsher-Smith Laboratories, Inc. announced Monday that a new saving and support program is available for patients who have been prescribed Qudexy XR extended-release capsules. Read More »

Genentech, a member of the Roche group, said on Friday that the U.S. Food and Drug Administration (FDA) approved Lucentis, the first eye medicine sanctioned to treat diabetic retinopathy (DR) with diabetic macular edema (DME). Read More »

Alkermes, PLC, said on Monday that it has produced positive results from a phase one, randomized, double-blind clinical study of ALKS 8700, an oral monomethyl fumarate (MMF) molecule in development as a multiple sclerosis (MS) treatment. Read More »

Daiichi Sankyo Company, Ltd. announced on Monday that SAVAYSA, a once-daily, oral, selective factor Xa-inhibitor, is now available in pharmacies within the United States. Read More »

Novo Nordisk and Karolinska Institutet signed a collaboration agreement on Monday Read More »

TeaserMylan Inc. confirmed Monday that it and its subsidiary, Mylan Pharmaceuticals, have been sued by Onyx Pharmaceuticals, Bayer Healthcare LLC and Bayer Healthcare Pharmaceuticals Inc. in connection to an application to make a generic form of NEXAVAR. Read More »

The Generic Pharmaceutical Association (GPhA) announced its 2015 executive committee and board of directors on Monday. Read More »